english

Moderna developing two-in-one booster shot for Covid-19 and flu

Moderna has announced that it is developing a single-dose vaccine to bring to the market that will combine a two-in-one booster shot that protects against both Covid-19 and flu.

On Thursday, drugmaker Moderna unveiled its latest innovation in the fight against Covid-19 – a “pan-respiratory annual booster vaccine” that combines a booster against Covid-19 and one against regular flu.

“Our number one priority as a company right now is to bring to market a pan-respiratory annual booster vaccine, which we plan to always customize and upgrade,” said CEO Stéphane Bancel.

Moderna is not the first to have announced the creation of a combined jab for Covid-19 and flu. American vaccine-maker Novavax announced on Wednesday that it has started an early stage trial in Australia to test its own two-in-one shot, having enrolled 640 healthy adult volunteers between the ages of 50 and 70.

Also on rt.com

(FILE PHOTO) © REUTERS/Dado Ruvic/Illustration/File Photo
Vaccine-maker Novavax kicks off trial for combined Covid-19/flu jab

Last week, Moderna submitted data to the European Medicines Agency for conditional approval for its Covid-19 vaccine to be used as a booster shot. Meanwhile, the US Food and Drug Administration greenlighted top-up doses of mRNA vaccines manufactured by Pfizer-BioNTech and Moderna in mid-August for people with compromised immune systems.

Moderna’s two-dose Covid-19 vaccine boasts a high efficacy rate of 93% six months after the administration of its second shot, barely waning from the 94.5% protection reported during its phase-three clinical trials.

The pharma company also said that it is “making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial.”

It also said its phase-two study of its authorized Covid-19 vaccine for children between 6 months and 12 years was ongoing. So far, the study is being carried out on 4,000 children between 6 and 12, while dosage selection studies are still underway for younger age groups.

Like this story? Share it with a friend!

source: RT




Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.

(Visited 10 times, 1 visits today)
Avatar
Marius Leontiuc
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica, Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
http://www.leontiucmarius.wordpress.com/cv

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *